Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

In the dose-expansion part of this open-label, phase I study, we explored the efficacy and safety of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced gastric cancer. Patients with advanced gastric cancer who had been previously treated with ≥2 lines of chemotherapy rec...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2023-04, Vol.29 (8), p.1460-1467
Hauptverfasser:	Shitara, Kohei, Hirao, Motohiro, Iwasa, Satoru, Oshima, Takashi, Komatsu, Yoshito, Kawazoe, Akihito, Sato, Yasuyoshi, Hamakawa, Takuya, Yonemori, Kan, Machida, Nozomu, Yuki, Satoshi, Suzuki, Takuya, Okumura, Shiori, Takase, Takao, Semba, Taro, Zimmermann, Bob, Teng, Angela, Yamaguchi, Kensei
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Trials: Targeted Therapy Furans - adverse effects Humans Ketones - adverse effects Progression-Free Survival Stomach Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!